Healthcare
Novartis to acquire Excellergy for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors for severe allergies
Excellergy to be acquired by Novartis for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors
BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines
Company highlights accelerating U.S. patient adds, international expansion, and upcoming milestones at Leerink conference.
- Palo Alto Woman Grapples with Grief After Losing Beloved Dog
- SG Americas Securities Boosts Stake in Archer Aviation
- Brayden Miller Cards Career-Best 66 as Bearcats Tie for 14th at The Goodwin
- Anthropic Accidentally Exposes Unreleased AI Model and Internal Data
- AppLovin Holdings Reduced by Elevatus Wealth Management
- Topsort Launches MCP Server to Power Agent-Operated Retail Media
